The table below shows CRISPR Therapeutics AG's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$108.90M
-$53.95M
$109.75M
$8.80M
-$135.24M
-$100.66M
Capital expenditure
$504.00K
$206.00K
$721.00K
$3.06M
$15.35M
$7.02M
Investing cash flow
-$410.74M
-$19.75M
-$97.80M
$117.83M
-$114.52M
-$167.90M
Dividends paid
-
-
-
-
CRSP operating cash flow (10-K history)
CRISPR Therapeutics AG reported operating cash flow of -$345.01M for fiscal year 2025. That is down 141.7% from -$142.77M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$52.86M (FY 2016) to -$345.01M. Figures come from the company's audited annual reports as filed with the SEC.
